End-User Testing Associated with the "Pregnancy and Lactation Labeling Rule" to Improve Health Communications and Prescribing Decisions in Pregnant Women - WAVE i

Segment 1 – Ob/Gyn

Dear [NAME]

The U.S. Food and Drug Administration, or FDA, is interested in learning about your experiences with prescription product labeling for pregnant women. We are contacting members of the [ACOG/Society for Maternal Fetal Medicine] database to invite you to participate in a 75-minute online focus group to get your feedback. Your input will be used to make recommendations and inform changes to prescription product labeling. Providers participating in these focus groups will receive a $300 token of appreciation for taking part in this project.

If you are interested, please follow the link below to complete a brief survey to determine if you are a good fit for the focus group. These questions will take no more than 5 minutes to answer.

<LINK>

This research is being conducted by Westat, a research company, on behalf of the FDA. If you are eligible, a representative from Westat will call you to schedule your participation in the focus group.

Thank you,

[Westat contact]

Segment 2 – Family Medicine

Dear [NAME]

The U.S. Food and Drug Administration, or FDA, is interested in learning about your experiences with prescription product labeling for pregnant women. We are contacting members of the American Academy of Family Physicians database to invite you to participate in a 75-minute online focus group to get your feedback. Your input will be used to make recommendations and inform changes to prescription product labeling. Providers participating in these focus groups will receive a $300 token of appreciation for taking part in this project.

If you are interested, please follow the link below to complete a brief survey to determine if you are a good fit for the focus group. These questions will take no more than 5 minutes to answer.

<LINK>

This research is being conducted by Westat, a research company, on behalf of the FDA. If you are eligible, a representative from Westat will call you to schedule your participation in the focus group.

Thank you,

[Westat contact]

Segment 3 – Other specialty physicians

Dear [NAME]

The U.S. Food and Drug Administration, or FDA, is interested in learning about your experiences with prescription product labeling for pregnant women. We are contacting members of the [American Psychiatric Association/American Academy of Neurology/American College of Gastroenterology/American Gastroenterological Association] database to invite you to participate in a 75-minute online focus group to get your feedback. Your input will be used to make recommendations and inform changes to prescription product labeling. Providers participating in these focus groups will receive a $300 token of appreciation for taking part in this project.

If you are interested, please follow the link below to complete a brief survey to determine if you are a good fit for the focus group. These questions will take no more than 5 minutes to answer.

<LINK>

This research is being conducted by Westat, a research company, on behalf of the FDA. If you are eligible, a representative from Westat will call you to schedule your participation in the focus group.

Thank you,

[Westat contact]